Table 2. Patient and Treatment Characteristics in the RADAR and DART Cohorts.
| Characteristic | EBRT duration, No. (%) | EBRT+BT duration, No. (%) | |||
|---|---|---|---|---|---|
| RADAR 6 mo | RADAR 18 mo | DART 28 mo | RADAR 6 mo | RADAR 18 mo | |
| No. | 85 | 96 | 91 | 101 | 102 |
| Follow-up, median (IQR) | 10.1 (8.2-11.1) | 10 (7.3-10.9) | 5.4 (4.1-7.1) | 11 (8.6-12) | 11 (9.6-11.8) |
| Age at treatment, y | 69.5 (63.8-73.7) | 69.9 (64.7-74.2) | 70.2 (64.4-74.5) | 66.6 (60.4-72.3) | 66.5 (61.3-71.5) |
| cT category | |||||
| T1, T2 | 45 (52.9) | 53 (55.2) | 53 (58.2) | 24 (23.8) | 27 (26.5) |
| T3, T4 | 40 (47.1) | 43 (44.8) | 38 (41.8) | 77 (76.2) | 75 (73.5) |
| iPSA, ng/mL | |||||
| Median (IQR) | 21.8 (10.8-42.8) | 18.5 (10.9-30) | 12.4 (7.1-26.2) | 16 (10-28) | 17 (10-28.6) |
| >20 | 46 (54.1) | 47 (49) | 36 (39.6) | 39 (38.6) | 41 (40.2) |
| Gleason grade groupa | |||||
| 1 | 8 (9.4) | 7 (7.3) | 12 (13.2) | 1 (1) | 2 (2) |
| 2 | 21 (24.7) | 29 (30.2) | 20 (22) | 16 (15.8) | 12 (11.8) |
| 3 | 14 (16.5) | 12 (12.5) | 13 (14.3) | 29 (28.7) | 22 (21.6) |
| 4 | 25 (29.4) | 23 (24) | 33 (36.3) | 25 (24.8) | 34 (33.3) |
| 5 | 17 (20) | 25 (26) | 13 (14.3) | 30 (29.7) | 32 (31.4) |
Abbreviations: DART, Deprivación Androgénica y Radio Terapía (Androgen Deprivation and Radiation Therapy) 01/05 trial; EBRT, external beam radiotherapy; EBRT+BT, external beam radiotherapy plus brachytherapy boost; iPSA, initial prostate-specific antigen; RADAR, the Randomized Androgen Deprivation and Radiotherapy 03/04 trial.
a
Primary and secondary Gleason grades were not available for the DART cohort.